SCHD has outperformed the S&P 500 in 2026 by acting countercyclically during the tech and semiconductor downturn, thanks to its sector mix and annual rebalancing. The fund's removal of Broadcom in March 2024, initially seen as risky, positioned it well against later market corrections. In March 2026, SCHD rotated into Health Care stocks, now the largest sector in its portfolio, enhancing its diversification. Despite a lower yield, SCHD is rated a BUY for its income potential and diversification benefits against growth and AI-focused investments, all while maintaining a low expense ratio of 0.06%.
The Schwab U.S. Dividend Equity ETF (SCHD) has defied bearish macroeconomic conditions by delivering strong returns, largely due to its top holdings such as Abbott Laboratories (ABT), Merck (MRK), and Amgen (AMGN) which posted significant gains after...
The Schwab U.S. Dividend Equity ETF (SCHD) has outperformed the S&P 500 in 2026, returning 27.92% through August compared to the S&P 500's 13.85%. This strong performance is due to SCHD's focus on dividend-paying sectors like semiconductors, healthca...
Vanguard Dividend Appreciation ETF (VIG) intentionally excludes the top 25% highest-yielding stocks from its index, reducing the income investors receive. This methodology aims to avoid potentially risky high yields but also screens out some strong d...
Dividend stocks have resumed accelerating profit growth after a multi-year slowdown, supporting the Schwab U.S. Dividend Equity ETF (SCHD) to potentially outperform the broader market. Key drivers include benefits from AI, improved economic condition...
In 2026, dividend equity ETFs have outperformed both 10-year Treasuries and the S&P 500 index, with Schwab U.S. Dividend Equity ETF (SCHD) leading with a 27.06% gain year-to-date. This outperformance is driven by sector composition and price apprecia...
